


**Product Name** : AS2676293  
**Cat. No.** : PC-21026  
**CAS No.** : 1393999-79-5  
**Molecular Formula** : C<sub>18</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O  
**Molecular Weight** : 378.33  
**Target** : NF-κB  
**Solubility** : 10 mM in DMSO



CAS: 1393999-79-5

## Biological Activity

AS2676293 (AS 2676293) is an orally active small-molecule receptor activator of nuclear factor-κB ligand (**RANKL**) inhibitor, inhibits RANKL-induced osteoclastogenesis using RAW264 cells with IC<sub>50</sub> of 0.19 μM.

AS2676293 (0.3-3 mg/kg, oral) inhibited bone loss significantly in RANKL-induced osteopenic mice.

AS2676293 markedly inhibited bone metastasis of human breast cancer cells MDA-MB-231-5a-D-Luc2 as well as tumour-induced osteolysis.

AS2676293 suppressed RANKL-mediated tumour migration in the transwell assay and inhibited bone metastasis of the murine cell line B16F10, which is known not to trigger osteoclast activation.

## References

Junji Miyata, et al. *Bioorg Med Chem Lett.* 2012 Sep 1;22(17):5681-4.  
Vagelis Rinotas, et al. *Int J Mol Sci.* 2023 Jul 10;24(14):11290.  
Nakai Y, et al. *Bone Res.* 2019 Jan 3;7:1. doi: 10.1038/s41413-018-0036-5.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: [tech@probechem.com](mailto:tech@probechem.com)